摘要
目的：观察替吉奥联合奥沙利铂治疗晚期胃癌的疗效和安全性。方法30例患者随机分为两组各15例，实验组给予替吉奥胶囊(80mg/m2)/d，分2次口服，d1-14；奥沙利铂130mg/m2，静脉滴注，d1。对照组给予替加氟800mg/m2静脉滴注， d1-5；亚叶酸钙100mg静脉滴注，d1-5；奥沙利铂130mg/m2，静脉滴注，d1。3周为1个周期，化疗2周期后评价疗效。结果两组总有效率无统计学差异(P >0.05)，两组主要的毒副反应均为消化道反应、血液学毒性及外周神经毒性。结论替吉奥胶囊联合奥沙利铂治疗进展期胃癌安全、有效。
Abstract
Objective To observe therapeutic effect and safety of gimeracil and oteracil porassium capsules combined with oxaliplatin in the treatment of advanced gastric cancer. Methods All 30 cases were divided into two groups randomly, the trial group(15 cases), TS-1 capsule(80mg/m2)/d, twice a day peroral, d1-14; oxaliplatin 130mg/m2,intravenous drip, d1. The control groups(15 cases), tegafur 800mg/m2, intravenous drip, d1-5; CF 100mg,intravenous drip, d1-5;oxaliplatin 130mg/m2, intravenous drip, d1. One treatment cycle covered 3 weeks. The effects were evaluated after 2 cycles. Results The effective rate was 33.3% in the trial group, and 26.7% in the control group(P >0.05). The main toxicities were gastrointestinal reactions, bonemarrow toxicity and peripheral neurotoxicity. Conclusion TS-1 capsule combined with oxaliplatin is safe and effective in the treatment of advanced gastric cancer.
NETL
NSTL
维普
万方数据